Drug Safety Newsletter – Edition 118 – 25 March 2025
25/03/2025
Medicines for human use
Safety update
The latest edition of the HPRA newsletter includes important updates to support the safe and appropriate use of the following medicines:
- Glatiramer acetate: Anaphylactic reactions may occur months up to years after treatment initiation
- Medroxyprogesterone acetate: Risk of meningioma and measures to minimise this risk
- Product information updates recommended by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)
- Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter